Literature DB >> 7398759

On the mode of action of ergometrine in the isolated dog coronary artery.

M Sakanashi, K I Yonemura.   

Abstract

Coronary vasoconstrictor responses to ergometrine were examined in spiral coronary arterial preparations of dogs. Either ergometrine or serotonin (5-HT) produced dose-dependent contractions of the strips. Methysergide significantly depressed the contractions induced by ergometrine or 5-Ht. Dihydroergotamine and phentolamine depressed constrictor responses to ergometrine, while phenoxybenzamine did not. The 5-HT antagonistic action of phentolamine was stronger than that of phenoxybenzamine. The results indicate that ergometrine may act on coronary arteries mainly through activation of 5-HT receptors.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7398759     DOI: 10.1016/0014-2999(80)90038-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  4 in total

1.  Actions of non-peptide ergot alkaloids at 5-HT1-like and 5-HT2 receptors mediating vascular smooth muscle contraction.

Authors:  S J MacLennan; G R Martin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-08       Impact factor: 3.000

2.  Influence of the endothelium, nitric oxide and serotonergic receptors on coronary vasomotor responses evoked by ergonovine in conscious dogs.

Authors:  D Karila-Cohen; E Delpy; J L Dubois-Randé; L Puybasset; L Hittinger; J F Giudicelli; A Berdeaux
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

3.  Comparison of contractile responses to 5-hydroxytryptamine and sumatriptan in human isolated coronary artery: synergy with the thromboxane A2-receptor agonist, U46619.

Authors:  T M Cocks; B K Kemp; D Pruneau; J A Angus
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

4.  Mechanisms of the ergonovine-induced vasoconstriction in the rabbit main coronary artery.

Authors:  A Suyama; H Kuriyama
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-07       Impact factor: 3.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.